Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

Just a week after the FDA updated its stance on new COVID-19 | The CDC's recommended immunization schedule no longer includes ...

Panel members had questions about whether a new FDA proposal to require randomized trials for vaccines in healthy adults ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The CDC will no longer recommend routine Covid shots for healthy children and pregnant women, Health and Human Services Secretary Robert F. Kennedy Jr. announced.

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.